Regenerative Treatments
for Ophthalmic Diseases

Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases

NRO-1

A  POTENTIAL DISEASE MODIFYING TREATMENT

Neuroptika is leveraging insights into the relationship between nerve degeneration and ophthalmic diseases to develop transformative treatments.

NRO-1, Neuroptika's lead therapy, is a nerve regenerative therapeutic that can treat the underlying cause of degenerative ophthalmic diseases.

Corneal Nerve Degeneration

Retinal Ganglion Cell Degeneration

 

Axonal regeneration of corneal sensory nerves

2. ACCELERATES

Neurite elongation in trigeminal ganglion (peripheral) and retinal ganglion (central) cells

3. PROMOTES

1. RELEASES

Glial cell-derived neurotrophic factor (GDNF)

NRO-1 PROGRAMS

NRO-1 has successfully completed a Phase 1 study.  A Phase 2 study for dry eye disease is ongoing.

PHASE 1

PHASE 2

PRECLINICAL

 

Functional Benefits of NRO-1

 
 

BACK TO TOP

CONTACT NEUROPTIKA

1770 Massachusetts Avenue, Suite 163 Cambridge, MA  02140

United States

Copyright, Neuroptika 2019. All rights reserved.  Terms of site use  |  Privacy Policy